Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemcentinib + erlotinib
- Development stage
- Phase 2
- Lead developer
- BerGenBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of bemcentinib (BGB324), a first-in-class, oral, selective and potent AXL kinase inhibitor, and erlotinib, an EGFR tyrosine kinase inhibitor. This combination is being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations. AXL overexpression is implicated in the development of resistance to EGFR inhibitors, and AXL inhibition by bemcentinib has been shown to abrogate resistance to EGFR inhibitors in vivo.
- Other names
- bemcentinib + erlotinib
02
Targets
AXL (AXL receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on bemcentinib + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemcentinib + erlotinib.